Related Experiment Videos
[Botulinum toxin in urology. An inventory]
H Schulte-Baukloh1, H H Knispel
1Urologische Abteilung, St. Hedwig Kliniken GmbH, Akademisches Lehrkrankenhaus der Universitätsmedizin Berlin, Campus Charité. H.Schulte-Baukloh@alexius.de
Der Urologe. Ausg. A
|July 28, 2004
Summary
Botulinum toxin (BTX) offers potent treatment for various voiding disorders, including neurogenic and non-neurogenic types. Despite its effectiveness, BTX lacks formal approval for urologic applications due to insufficient evidence-based studies.
Area of Science:
- Urology
- Neurology
Context:
- Botulinum toxin (BTX) has been utilized in neurourology for 15 years.
- Initial applications focused on neurogenic detrusor-sphincter dyssynergia.
- Indications have expanded to include neurogenic and non-neurogenic detrusor hyperactivity, dysfunctional voiding, and pelvic pain syndromes.
Purpose:
- To review the current applications and limitations of botulinum toxin in treating voiding disorders.
- To highlight the potential benefits of BTX in neurourology despite a lack of formal approval.
Summary:
- BTX demonstrates high potency in managing both neurogenic and non-neurogenic voiding disorders.
- Recommended for insufficient detrusor contractility (sphincter injections) and refractory neurogenic detrusor hyperactivity (detrusor injections).
- Lack of robust evidence-based studies currently prevents formal approval for urologic use, despite significant clinical need.
Impact:
- Addresses the unmet need for effective treatments in complex voiding dysfunction.
- Suggests a promising therapeutic avenue for patients unresponsive to conventional therapies.
- Highlights the need for further research to support broader clinical adoption of BTX in urology.